Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
News provided byACCESSWIRE
Sep 19, 2023, 8:15 AM ET
~ Moderated Session to Review Latest Data as Recently Presented ~
SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced they will host a Research and Development ("R&D") FAQ Session to discuss educational session held at PAINWeek where they presented their approach to delivering the Next Generation of analgesics.
The Symposium "Severe Pain - Next Generation Solutions - PF614/ PF614-MPAR" featured experts in pain management and prescription drug abuse, Dr. Jeff Gudin from the University of Miami, and Dr. Richard Dart from the Rocky Mountain Poison and Drug Center in Denver, as well as Dr. William Schmidt, Chief Medical Officer of Ensysce who expanded on the recent developments with PF614 and PF614-MPAR. The meeting attracted attention from experts and received extremely positive feedback from attendees.
This R&D FAQ Session will provide a summary of the event and discuss the current state of Ensysce's programs being developed for severe pain. Dr. Lynn Kirkpatrick, Ensysce CEO, and Dr. William Schmidt, Ensysce Chief Medical Officer, will discuss the event in moderated format with Geoff Birkett, Ensysce Chief Commercial Officer.
R&D FAQ Session
Date: Thursday, September 21, 2023
Time: 10:00am ET
Webinar: ENSC R&D FAQ Session
Please pre-submit questions to ENSC@mzgroup.us no later than 8:00am ET on Thursday, September 21, 2023.
PF614 is a Trypsin Activated Abuse Protected (TAAPTM) product designed as a delayed onset extended-release oxycodone prodrug. TAAPTM chemical modification inactivates the active ingredient in Ensysce's products including PF614 until they are swallowed. This provides abuse deterrence, resistance to manipulation and other forms of recreational drug abuse, while providing a high degree of pain relief for those who require opioid analgesics for 24/7 round-the-clock severe pain.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAPä) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
Ensysce Biosciences Investor Relations Contact:
MZ Group North America
SOURCE: Ensysce Biosciences Inc.
View source version on accesswire.com:
NOTE: This content is not written by or endorsed by "c", its advertisers, or Nexstar Media Inc.